9969 Stock Overview
A biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
InnoCare Pharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$5.93 |
| 52 Week High | HK$7.92 |
| 52 Week Low | HK$4.03 |
| Beta | 1.02 |
| 1 Month Change | -3.73% |
| 3 Month Change | 8.41% |
| 1 Year Change | -7.49% |
| 3 Year Change | -60.57% |
| 5 Year Change | n/a |
| Change since IPO | -56.20% |
Recent News & Updates
Recent updates
Shareholder Returns
| 9969 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | -3.9% | -3.9% | -0.5% |
| 1Y | -7.5% | -5.7% | 19.9% |
Return vs Industry: 9969 underperformed the Hong Kong Biotechs industry which returned -5.7% over the past year.
Return vs Market: 9969 underperformed the Hong Kong Market which returned 19.9% over the past year.
Price Volatility
| 9969 volatility | |
|---|---|
| 9969 Average Weekly Movement | 9.1% |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in HK Market | 18.6% |
| 10% least volatile stocks in HK Market | 4.1% |
Stable Share Price: 9969 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 9969's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 1,109 | Jasmine Cui | www.innocarepharma.com |
InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases in China. The company develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom’s macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder. It also developing ICP-192, a pan-FGFR inhibitor that is in a Phase I/II clinical trial for the treatment of solid tumor patients, including cholangiocarcinoma, and head and neck cancer; ICP-723, a pan-TRK inhibitor, which is in Phase I clinical trial to treat neurotrophic tyrosine receptor kinase fusion positive cancers; ICP-332, a novel tyrosine kinase 2 inhibitor that is in a Phase I clinical trial for the treatment of autoimmune diseases; and ICP-B02, a bispecific antibody for the treatment of lymphoma.
InnoCare Pharma Limited Fundamentals Summary
| 9969 fundamental statistics | |
|---|---|
| Market cap | HK$12.45b |
| Earnings (TTM) | -HK$400.19m |
| Revenue (TTM) | HK$958.01m |
10.9x
P/S Ratio-26.1x
P/E RatioIs 9969 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9969 income statement (TTM) | |
|---|---|
| Revenue | CN¥898.92m |
| Cost of Revenue | CN¥125.58m |
| Gross Profit | CN¥773.34m |
| Other Expenses | CN¥1.15b |
| Earnings | -CN¥375.51m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.21 |
| Gross Margin | 86.03% |
| Net Profit Margin | -41.77% |
| Debt/Equity Ratio | 20.9% |
How did 9969 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 00:39 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
InnoCare Pharma Limited is covered by 17 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peng Zou | China International Capital Corporation Limited |
| Tan Huan Gan | Citic Securities Co., Ltd. |
| Shitong Han | Citic Securities Co., Ltd. |